Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 14,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Influenza
Interventions: Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine, Placebo; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 11,404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Denver, Colorado • Pembroke Pines, Florida • South Miami, Florida + 13 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Petosemtamab, Investigator's Choice; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 60
States / cities: Mobile, Alabama • Prescott, Arizona • Scottsdale, Arizona + 52 more

Conditions: Beta-Thalassemia
Interventions: VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID, Placebo; Drug
Lead sponsor: Vifor (International) Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Whittier, California

Conditions: Motion Sickness
Interventions: DPI-386 Nasal Gel, Placebos; Drug
Lead sponsor: Repurposed Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Allergic Conjunctivitis
Interventions: TL-925, Placebo; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Smyrna, Tennessee

Conditions: Idiopathic Gastroparesis
Interventions: CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mg; Drug
Lead sponsor: CinDome Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 85
States / cities: Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 78 more

Conditions: Obesity
Interventions: APD356; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Lennox Gastaut Syndrome
Interventions: Clemizole HCl, Placebo; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more

Conditions: Psoriasis
Interventions: D-2570 Tablet, Placebo Tablets; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 16 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: BBT002, Placebo; Drug
Lead sponsor: Bambusa Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Amisodin, Placebo; Drug · Other
Lead sponsor: PRG Science & Technology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postherpetic Neuralgia
Interventions: SLC022, Placebo; Drug
Lead sponsor: Solace Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 19
States / cities: Sierra Vista, Arizona • Mission Viejo, California • Orlando, Florida + 16 more

Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Interventions: Belimumab, Placebo; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more

Conditions: Healthy Volunteers (Meningococcal Infection)
Interventions: MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,627 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 65
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more

Conditions: Thyroid Lobectomy
Interventions: Pre-Surgery Survey, Post-Surgery Surveys; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions: TEPEZZA, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 113
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more

Conditions: Liver Fibrosis, Hepatic Cirrhosis
Interventions: AZD2389; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Chandler, Arizona • Rialto, California • Atlanta, Georgia + 3 more

Conditions: Venous Ulcers
Interventions: Nitric Oxide 200ppm Group B; Drug
Lead sponsor: Nitric BioTherapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Denver, Colorado • San Antonio, Texas

Conditions: Congenital Hyperinsulinism
Interventions: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC; Drug
Lead sponsor: Rezolute; Other
Eligibility: 3 Months to 45 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Schizophrenia or Schizoaffective Disorder
Interventions: AMG 581, Placebo, Midazolam; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Insomnia
Interventions: Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 12
States / cities: Tucson, Arizona • Little Rock, Arkansas • Brandon, Florida + 8 more

Conditions: Submental Fat
Interventions: LIPO-202, Placebo for LIPO-202; Drug
Lead sponsor: Neothetics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Beverly Hills, California • Manhattan Beach, California • Greenwood Village, Colorado + 8 more

Search by objective public record fields.

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

Safety and Efficacy of APD356 in the Treatment of Obesity

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers

RZ358 Treatment for Congenital Hyperinsulinism

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat